======= PARP3 =======
== Gene Information ==
* **Official Symbol**: PARP3
* **Official Name**: poly(ADP-ribose) polymerase family member 3
* **Aliases and Previous Symbols**: N/A
* **Entrez ID**: [[https://www.ncbi.nlm.nih.gov/gene/?term=10039|10039]]
* **UniProt**: [[https://www.uniprot.org/uniprot/Q9Y6F1|Q9Y6F1]]
* **Interactions**: [[https://thebiogrid.org/search.php?search=PARP3&organism=9606|BioGRID]]
* **PubMed articles**: [[https://www.ncbi.nlm.nih.gov/pubmed/?term=gene%20PARP3|Open PubMed]]
* **OMIM**: [[https://omim.org/entry/607726|Open OMIM]]
== Function Summary ==
* **Entrez Summary**: N/A
* **UniProt Summary**: Involved in the base excision repair (BER) pathway, by catalyzing the poly(ADP-ribosyl)ation of a limited number of acceptor proteins involved in chromatin architecture and in DNA metabolism. This modification follows DNA damages and appears as an obligatory step in a detection/signaling pathway leading to the reparation of DNA strand breaks. May link the DNA damage surveillance network to the mitotic fidelity checkpoint. Negatively influences the G1/S cell cycle progression without interfering with centrosome duplication. Binds DNA. May be involved in the regulation of PRC2 and PRC3 complex-dependent gene silencing. {ECO:0000269|PubMed:16924674}.
|WGR|
|PARP reg|
|PARP|
|negative regulation of telomerase RNA reverse transcriptase activity|
|regulation of telomerase RNA reverse transcriptase activity|
|DNA ADP-ribosylation|
|protein localization to site of double-strand break|
|NAD DNA ADP-ribosyltransferase activity|
|negative regulation of isotype switching|
|positive regulation of DNA ligation|
|regulation of DNA ligation|
|protein poly-ADP-ribosylation|
|negative regulation of immunoglobulin mediated immune response|
|negative regulation of B cell mediated immunity|
|protein mono-ADP-ribosylation|
|negative regulation of immunoglobulin production|
|protein auto-ADP-ribosylation|
|negative regulation of telomerase activity|
|positive regulation of double-strand break repair via nonhomologous end joining|
|protein ADP-ribosylase activity|
|regulation of double-strand break repair via nonhomologous end joining|
|NAD+ ADP-ribosyltransferase activity|
|protein ADP-ribosylation|
|negative regulation of B cell activation|
|positive regulation of double-strand break repair|
|regulation of isotype switching|
|negative regulation of production of molecular mediator of immune response|
|negative regulation of lymphocyte mediated immunity|
|regulation of mitotic spindle organization|
|negative regulation of DNA biosynthetic process|
|negative regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains|
|regulation of spindle organization|
|negative regulation of adaptive immune response|
|catalytic activity|
|negative regulation of DNA recombination|
|negative regulation of leukocyte mediated immunity|
|regulation of B cell mediated immunity|
|regulation of immunoglobulin mediated immune response|
|regulation of telomerase activity|
|site of double-strand break|
|protein localization to chromosome|
|regulation of immunoglobulin production|
|positive regulation of DNA repair|
|regulation of double-strand break repair|
|DNA modification|
|positive regulation of response to DNA damage stimulus|
|telomere maintenance|
|telomere organization|
|regulation of DNA recombination|
|regulation of DNA biosynthetic process|
|negative regulation of immune effector process|
|negative regulation of DNA metabolic process|
|regulation of DNA repair|
|regulation of production of molecular mediator of immune response|
|centriole|
|regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains|
|negative regulation of lymphocyte activation|
|negative regulation of immune response|
|regulation of lymphocyte mediated immunity|
|regulation of adaptive immune response|
|negative regulation of leukocyte activation|
|double-strand break repair|
|regulation of microtubule cytoskeleton organization|
|positive regulation of DNA metabolic process|
|negative regulation of cell activation|
|regulation of leukocyte mediated immunity|
|regulation of B cell activation|
|regulation of response to DNA damage stimulus|
|regulation of microtubule-based process|
|negative regulation of transferase activity|
|anatomical structure homeostasis|
|regulation of DNA metabolic process|
|negative regulation of immune system process|
|regulation of immune effector process|
|DNA repair|
|regulation of lymphocyte activation|
|regulation of cytoskeleton organization|
|regulation of leukocyte activation|
|regulation of mitotic cell cycle|
|regulation of cell activation|
|regulation of cellular response to stress|
|protein localization to organelle|
|DNA metabolic process|
|regulation of cell cycle process|
|cellular response to DNA damage stimulus|
|negative regulation of catalytic activity|
|nucleolus|
|negative regulation of developmental process|
|regulation of transferase activity|
|chromosome organization|
|negative regulation of molecular function|
|regulation of immune response|
|regulation of cell cycle|
|negative regulation of multicellular organismal process|
|regulation of organelle organization|
|negative regulation of cellular macromolecule biosynthetic process|
|negative regulation of nucleobase-containing compound metabolic process|
|negative regulation of macromolecule biosynthetic process|
|regulation of response to stress|
|negative regulation of cellular biosynthetic process|
|negative regulation of biosynthetic process|
|cellular protein localization|
|cellular macromolecule localization|
|negative regulation of response to stimulus|
|homeostatic process|
|regulation of immune system process|
|cellular response to stress|
|positive regulation of nucleobase-containing compound metabolic process|
\\
=== CRISPR Data ===
^Screen^Score^
|[[:results:exp527|Tanespimycin 14μM R08 exp527]]|-1.9|
|[[:results:exp340|BN82002 4μM R07 exp340]]|1.72|
|[[:results:exp473|Cincreasin 100μM R08 exp473]]|1.75|
|[[:results:exp283|Glyphosate 1000μM R06 exp283]]|1.91|
|[[:results:exp454|Bafilomycin-A1 0.009μM R08 exp454]]|2|
|[[:results:exp128|GSK591 2.6μM R03 exp128]]|2.18|
|[[:results:exp187|proTAME 5μM R04 exp187]]|2.48|
^Gene^Correlation^
|[[:human genes:g:golga8o|GOLGA8O]]|0.483|
|[[:human genes:t:tceb3c|TCEB3C]]|0.463|
|[[:human genes:v:vasn|VASN]]|0.462|
|[[:human genes:t:tceb3cl|TCEB3CL]]|0.453|
|[[:human genes:x:xylt2|XYLT2]]|0.452|
|[[:human genes:p:psmb4|PSMB4]]|0.445|
|[[:human genes:k:krt78|KRT78]]|0.441|
|[[:human genes:c:cep192|CEP192]]|0.441|
|[[:human genes:m:mt1e|MT1E]]|0.435|
|[[:human genes:p:pole|POLE]]|0.429|
|[[:human genes:n:npipb5|NPIPB5]]|0.428|
|[[:human genes:r:rps2|RPS2]]|0.426|
|[[:human genes:o:or11h6|OR11H6]]|0.424|
|[[:human genes:c:chd4|CHD4]]|0.424|
|[[:human genes:i:ik|IK]]|0.423|
|[[:human genes:g:golga6l3|GOLGA6L3]]|0.419|
|[[:human genes:o:or10g3|OR10G3]]|0.418|
|[[:human genes:r:rpl37a|RPL37A]]|0.418|
|[[:human genes:p:pan3|PAN3]]|0.415|
|[[:human genes:n:nupl1|NUPL1]]|0.414|
|[[:human genes:a:aqr|AQR]]|0.413|
|[[:human genes:n:nop16|NOP16]]|0.412|
|[[:human genes:r:rffl|RFFL]]|0.409|
|[[:human genes:o:orc1|ORC1]]|0.407|
|[[:human genes:t:tceb3cl2|TCEB3CL2]]|0.407|
|[[:human genes:d:dtl|DTL]]|0.406|
|[[:human genes:t:twistnb|TWISTNB]]|0.404|
|[[:human genes:h:hist2h3c|HIST2H3C]]|0.404|
|[[:human genes:c:col2a1|COL2A1]]|0.404|
|[[:human genes:h:hist2h3a|HIST2H3A]]|0.404|
|[[:human genes:a:aamp|AAMP]]|0.402|
|[[:human genes:g:golga6l4|GOLGA6L4]]|0.401|
|[[:human genes:n:nup160|NUP160]]|0.4|
Global Fraction of Cell Lines Where Essential: 0/726
^Tissue^Fraction Of Cell Lines Where Essential^
|1290807.0|0/1|
|909776.0|0/1|
|bile duct|0/28|
|blood|0/28|
|bone|0/25|
|breast|0/33|
|central nervous system|0/56|
|cervix|0/4|
|colorectal|0/17|
|esophagus|0/13|
|fibroblast|0/1|
|gastric|0/15|
|kidney|0/21|
|liver|0/20|
|lung|0/75|
|lymphocyte|0/14|
|ovary|0/26|
|pancreas|0/24|
|peripheral nervous system|0/16|
|plasma cell|0/15|
|prostate|0/1|
|skin|0/24|
|soft tissue|0/7|
|thyroid|0/2|
|upper aerodigestive|0/22|
|urinary tract|0/29|
|uterus|0/5|
== Essentiality in NALM6 ==
* **Essentiality Rank**: 2400
* **Expression level (log2 read counts)**: 3.61
{{:chemogenomics:nalm6 dist.png?nolink |}}